Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03117400




Registration number
NCT03117400
Ethics application status
Date submitted
11/04/2017
Date registered
18/04/2017
Date last updated
29/06/2023

Titles & IDs
Public title
Systematic Description of the Post EMR Defect
Scientific title
Visible Vessels do Not Predict Clinically Significant Bleeding After EMR - a Systematic Description of the Post EMR Defect
Secondary ID [1] 0 0
HREC/15/5/5.3 (4272)
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Delayed Bleeding Post EMR 0 0
Large Laterally Spreading Lesion in the Colon 0 0
Endoscopic Mucosal Resection 0 0
Condition category
Condition code

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Bland blue defect - The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is blue without any other defect features (as described in the second group, 'non bland blue defect'). The blue is the result of the submucosal injection of dye (indigo carmine), used to lift lesions before starting the resection.

Non bland blue defect - The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is not just blue, but contains other defect features, such as visible vessels, herniation of vessels, submucosal fat, exposed muscle, fibrous bands, submucosal haemorrhage or non stained submucosa.
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Defect features predicting clinically significant post EMR bleeding
Timepoint [1] 0 0
day of procedure until 2 weeks after the procedure
Secondary outcome [1] 0 0
Defect features predicting other adverse events
Timepoint [1] 0 0
day of procedure until 2 weeks after the procedure

Eligibility
Key inclusion criteria
- All patients referred for EMR of a LSL 20mm or larger

- Signed the informed consent
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Clips used during the EMR procedure to close the defect, totally or partially

- Inadequate images to adequately assess the defect

- Use of blood thinners which have not been ceased according to the current guidelines
for EMR

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/05/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/03/2017
Sample size
Target
Accrual to date
Final
482
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Westmead Hospital - Westmead
Recruitment postcode(s) [1] 0 0
2145 - Westmead

Funding & Sponsors
Primary sponsor type
Other
Name
Western Sydney Local Health District
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
To date there are no available data on the utility of the endoscopic mucosal resection (EMR)
defect in stratifying the risk of immediate or delayed adverse outcomes, particularly
clinically significant post EMR bleeding (CSPEB).

The investigators aimed to analyse the data to determine if any of these EMR defect features
allow us to estimate the risk of CSPEB. This will help endoscopists to identify defects with
a high risk of adverse outcomes and may translate into improved patient outcomes.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03117400
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Michael Bourke, MBBS, FRACP
Address 0 0
WSLHD
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03117400